Green_Earth
消息 | 簡介 | 相關文件 | 相關網站
IPCW405摘譯--IMPLEMENTATION OF PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH
日期:2003/10/15
作者:pc309a
附件下載:IPCW405-TRIPS協定與公共衛生杜哈宣言第六段之實施.doc
因為版本問題,開啟附件時可能會出現錯誤訊息,如「檔案已損毀」的訊息,請您忽略此訊息,即可正常開啟
World Trade Organization IP/C/W/405 28 August 2003 (03-4498) Council for Trade-Related Aspects of Intellectual Property Rights 文件代號 : IP/C/W/405 文件名稱 : TRIPS協定與公共衛生杜哈宣言第六段 之實施 登錄時間 : 2003年8月28日 摘譯 : 會員國之間取得共識,同意會員國可在強制授權的允許下得製造並出口有專利之藥品,而且任何會員國可進口該藥品,惟該藥品只能用於公共衛生用途上,不得作為商業或其他用途。文件中釐定藥品的涵蓋範圍,也對該藥品的進出口國家的資格、義務等事項做出相關規範。 implementation of paragraph 6 of the doha declaration on the trips agreement and public health Draft Decision of […] 2003 At its meeting of 28 August 2003, the Council for TRIPS approved the following draft decision and agreed to forward it to the General Council for adoption. _______________ The General Council, Having regard to paragraphs 1, 3 and 4 of Article IX of the Marrakesh Agreement Establishing the World Trade Organization ("the WTO Agreement"); Conducting the functions of the Ministerial Conference in the interval between meetings pursuant to paragraph 2 of Article IV of the WTO Agreement; Noting the Declaration on the TRIPS Agreement and Public Health (WT/MIN(01)/DEC/2) (the "Declaration") and, in particular, the instruction of the Ministerial Conference to the Council for TRIPS contained in paragraph 6 of the Declaration to find an expeditious solution to the problem of the difficulties that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face in making effective use of compulsory licensing under the TRIPS Agreement and to report to the General Council before the end of 2002; Recognizing, where eligible importing Members seek to obtain supplies under the system set out in this Decision, the importance of a rapid response to those needs consistent with the provisions of this Decision; Noting that, in the light of the foregoing, exceptional circumstances exist justifying waivers from the obligations set out in paragraphs (f) and (h) of Article 31 of the TRIPS Agreement with respect to pharmaceutical products; Decides as follows: For the purposes of this Decisio